- Tariffs benefit AI stocks, while Bristol-Myers Squibb and Bain Capital launch an immunology spinout.
Bristol-Myers Squibb and Bain Capital announced large deals regarding drug programs, including co-founding an acquired company, Aiolos Bio.
1 report, 1 independent
Updated Jun 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Bristol-Myers Squibb and Bain Capital announced large deals regarding drug programs, including co-founding an acquired company, Aiolos Bio.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Bain Capital provided initial $300M funding to a firm alongside Bristol-Myers Squibb, which received Fast Track designation for SLE.Sub-event
BMS and Bain Capital update their immunology spinout with new partnerships and acquisitions.1 source
Keep exploring
The entities involved
-
Bristol-Myers Squibb
American pharmaceutical company
-
Bain Capital
American alternative investment firm specialized in private equity, venture capital and credit products
Related events
- Bristol-Myers Squibb has taken ownership of Celgene's drug.
- Bristol-Myers Squibb and AstraZeneca announced a collaboration on advanced cancer drug development.
- Cocrystal Pharma and Bristol-Myers Squibb are competing for investment as healthcare companies.
- Bristol-Myers Squibb and Johnson & Johnson are both companies that are currently targets of LB Pharmaceuticals.